More particularly, potential strategies for combating macrophage chemotaxis, which is induced by CXCL10-contained EVs, includes the utilization of neutralizing CXCL10-antisera or the inhibition of the NASH-promoting kinases such as Mixed lineage kinase 3 (MLK3) that favors their release [64,65,89]. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatohepatitis.